An antibody-drug conjugate, rovalpituzumab tesirine (Rova-T) was designed to specifically target delta-like ligand 3 (DLL3), an inhibitory Notch ligand that is highly expressed in SCLC (80%) and other neuroendocrine tumors but minimally expressed in normal tissues [37]. The gene discussed is DLL3; the disease is small cell lung carcinoma.